These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 26573082

  • 1. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
    Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, Zapotocky M, De Moerloose B, Fynn A, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Forestier E, Salgado C, Balwierz W, Popa A, Rubnitz J, Raimondi S, Gibson B.
    J Clin Oncol; 2015 Dec 20; 33(36):4247-58. PubMed ID: 26573082
    [Abstract] [Full Text] [Related]

  • 2. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
    von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U.
    J Clin Oncol; 2010 Jun 01; 28(16):2682-9. PubMed ID: 20439630
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R, Hu X, Wang L, Cheng H, Lv S, Zhang W, Wang J, Yang J, Song X.
    Am J Hematol; 2017 Jan 01; 92(1):12-17. PubMed ID: 27673579
    [Abstract] [Full Text] [Related]

  • 4. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A.
    Oncol Rep; 2013 May 01; 29(5):1867-72. PubMed ID: 23467883
    [Abstract] [Full Text] [Related]

  • 5. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H.
    J Clin Oncol; 2001 May 15; 19(10):2705-13. PubMed ID: 11352963
    [Abstract] [Full Text] [Related]

  • 6. Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities.
    Wang B, Yang B, Ling Y, Zhang J, Hua X, Gu W, Yan F.
    Cancer Med; 2021 Feb 15; 10(3):1091-1102. PubMed ID: 33382538
    [Abstract] [Full Text] [Related]

  • 7. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH, L/MDS working party, Korean Society of Hematology.
    Ann Hematol; 2013 Jan 15; 92(2):163-71. PubMed ID: 23053179
    [Abstract] [Full Text] [Related]

  • 8. [Prognosis and chromosomal abnormalities in 79 children with t (8;21) acute myeloid leukemia].
    Chen YM, Liu TF, Ruan M, Zou Y, Chen XJ, Guo Y, Wang SC, Zhu XF.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct 15; 31(5):542-6. PubMed ID: 19968066
    [Abstract] [Full Text] [Related]

  • 9. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
    Wang B, Zhang J, Hua X, Li H, Wang Z, Yang B.
    Sci Rep; 2020 Jan 20; 10(1):685. PubMed ID: 31959790
    [Abstract] [Full Text] [Related]

  • 10. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
    Neubauer A, Maharry K, Mrózek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD.
    J Clin Oncol; 2008 Oct 01; 26(28):4603-9. PubMed ID: 18559876
    [Abstract] [Full Text] [Related]

  • 11. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
    Lai YY, Qiu JY, Jiang B, Lu XJ, Huang XJ, Zhang Y, Liu YR, Shi HL, Lu DP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct 01; 13(5):733-40. PubMed ID: 16277833
    [Abstract] [Full Text] [Related]

  • 12. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.
    J Clin Oncol; 2014 Jan 20; 32(3):219-28. PubMed ID: 24297940
    [Abstract] [Full Text] [Related]

  • 13. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
    Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D.
    Blood; 2011 Nov 17; 118(20):5409-15. PubMed ID: 21948298
    [Abstract] [Full Text] [Related]

  • 14. [Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)].
    Gritsaev SV, Martynkevich IS, Ziuzgin IS, Kariagina EV, Martynenko LS, Petrova EV, Tsybakova NIu, Ivanova MP, Kostroma II, Tiranova SA, Potikhonova NA, Abdulkadyrov KM.
    Ter Arkh; 2014 Nov 17; 86(7):45-52. PubMed ID: 25314777
    [Abstract] [Full Text] [Related]

  • 15. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H, Tanaka S, Miyamura T, Nakayama H, Shiba N, Shimada A, Terui K, Yuza Y, Koh K, Goto H, Kakuda H, Saito A, Hasegawa D, Iwamoto S, Taga T, Adachi S, Tomizawa D.
    Pediatr Blood Cancer; 2021 Jan 17; 68(1):e28736. PubMed ID: 32991072
    [Abstract] [Full Text] [Related]

  • 16. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.
    Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD.
    J Clin Oncol; 1999 Dec 17; 17(12):3767-75. PubMed ID: 10577848
    [Abstract] [Full Text] [Related]

  • 17. [Genetic prognostic factors in childhood acute myeloid leukemia].
    Reinhardt D, Von Neuhoff C, Sander A, Creutzig U.
    Klin Padiatr; 2012 Oct 17; 224(6):372-6. PubMed ID: 22821298
    [Abstract] [Full Text] [Related]

  • 18. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D.
    Lancet Oncol; 2010 Jun 17; 11(6):543-52. PubMed ID: 20451454
    [Abstract] [Full Text] [Related]

  • 19. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
    Sirohi B, Powles R, Singhal S, Smith K, Jones RL, Saso R, Kulkarni S, Treleaven J, Swansbury GJ, Potter M, Morgan G, Mehta J.
    Leuk Lymphoma; 2008 Dec 17; 49(12):2284-90. PubMed ID: 19052975
    [Abstract] [Full Text] [Related]

  • 20. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.
    Chin J Cancer; 2016 May 19; 35():46. PubMed ID: 27197573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.